Submission of outcome of the Board Meeting held on 14th November, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories reported Q2 FY26 revenue from operations of Rs. 3,751.64 lakhs, up sharply from Rs. 1,315.98 lakhs in Q2 FY25. Net profit for the quarter stood at Rs. 258.26 lakhs (vs Rs. 200.29 lakhs YoY), with basic EPS of Rs. 2.40. For the half year ended September 2025, total revenue was Rs. 6,293.18 lakhs and net profit Rs. 467.22 lakhs, compared to Rs. 369.20 lakhs in H1 FY25. The board approved these unaudited results along with the limited review report from Sathuluri & Co. Balance sheet shows total assets expanding to Rs. 10,070.45 lakhs (from Rs. 6,334.06 lakhs in March 2025), driven largely by higher trade receivables and inventories. The company also received Rs. 298.48 lakhs from share warrants and issued fresh equity during the period.
Strong revenue growth of nearly 3x year-on-year and a 29% rise in net profit signal improving business momentum in the bulk drugs/API segment. The rise in trade receivables (more than doubled) and fresh current borrowings of Rs. 1,232.67 lakhs need to be tracked for collection and leverage risk, while the equity infusion via warrants suggests expansion plans.